Human(ized) monoclonal antibodies in atopic patients - state of the art

Creative Commons License

Yalcin A. D., Onbasi K., Uzun R., Herth F., Schnabel P. A.

CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY, vol.45, pp.195-201, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 45
  • Publication Date: 2020
  • Doi Number: 10.5114/ceji.2020.97909
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, EMBASE, Directory of Open Access Journals
  • Page Numbers: pp.195-201
  • Kütahya Health Sciences University Affiliated: Yes


Asthma is an important chronic disease affecting a lot of people worldwide. Treatment options for asthma like biological agents are being developed more frequently nowadays. Despite a lot of treatment options, some patients still remain symptomatic. As more and more practitioners choose treatment with biologic agents as a convenient way of therapy, biologic agents and other valuable methods must be discovered in order to cope with a growing number of treatment agents. This manuscript emphasizes on new generation monoclonal human(ized) antibodies in asthmatics and off-label use. The first developed biologic agent is the anti-immunoglobulin E monoclonal antibody called omalizumab. Currently it is an approved treatment option for asthma.